Anemia and Bone Marrow Suppression after Intra
DOI:
https://doi.org/10.63682/jns.v13i1.8985Keywords:
Retinoblastoma, Intra-arterial chemotherapy, Anemia, Bone marrow suppression, Pediatric oncology, Hematologic toxicityAbstract
Background : To assess the incidence and severity of anemia and bone marrow suppression following intra-arterial chemotherapy in children diagnosed with retinoblastoma.
Methods:This prospective study was conducted from May 2023 to May 2024 at People's University of Medical and Health Sciences Nawabshah, enrolling 77 children with confirmed retinoblastoma who underwent IAC. Hematological indices including hemoglobin, white blood cell count, absolute neutrophil count, and platelet levels were recorded before and after each chemotherapy cycle. Adverse events were graded using CTCAE criteria. Statistical analysis was performed using SPSS version 25, with p < 0.05 considered significant.
Results: Post-treatment anemia was observed in 66.2% of patients, with 16.9% developing Grade 3–4 severity. Bone marrow suppression occurred in 49.4% of cases, with significant declines in hemoglobin (p < 0.001), WBC (p = 0.003), and platelet counts (p < 0.001). Blood transfusions were required in 28.6% of children. Treatment delays due to hematologic toxicity were noted in 15.6% of cases.
Conclusion: Although IAC is localized in administration, its systemic hematologic effects are clinically significant. Regular blood count monitoring and timely supportive interventions are essential to mitigate the risks of anemia and marrow suppression in pediatric retinoblastoma patients undergoing this therapy.
Downloads
Metrics
References
Tangella, A.V.J.C., The evolving role of intra-arterial chemotherapy in adult and pediatric cancers: A comprehensive review. 2023. 15(10).
Zeng, C., et al., Hemostatic effect of 3D-printed hip fixators in children with retinoblastoma after intra-arterial chemotherapy: a non-randomized controlled trial. 2024. 14(1): p. 27613.
Shah, A. and A.M. Leahey, Intravenous Chemotherapy for Retinoblastoma: A Pediatric Oncologist’s Perspective, in Global Perspectives in Ocular Oncology. 2023, Springer. p. 33-43.
Lee, D.H., et al., Incidence and risk factors for neutropenia after intra-arterial chemotherapy for retinoblastoma. 2023. 141(12): p. 1133-1138.
Sanati-Mehrizy, A., et al., Hematologic complications associated with intra-arterial chemotherapy for retinoblastoma treatment: a single institution experience. 2022. 44(4): p. 181-185.
Kolyvas, P., et al., Advanced interventional treatments in retinoblastoma management: a comprehensive review. 2024. 47(4): p. 407-415.
Luz, A.F.C., et al., The Paradigm of Efficacy of Chemotherapy in Association with Different Adjuvant Treatments for Retinoblastoma: A Systematic Review of Literature. 2024. 36(8): p. 255-271.
Huang, R., J. Boltze, and S.J.F.i.O. Li, Strategies for improved intra-arterial treatments targeting brain tumors: a systematic review. 2020. 10: p. 1443.
Roy, S.R. and F.J.I.J.G.I.M.B. Huque, A Review of Childhood Ocular, Orbital, and Surface Tumors with Updated Clinical Management. 2022. 1: p. 29-41.
Zahnreich, S. and H.J.C. Schmidberger, Childhood cancer: occurrence, treatment and risk of second primary malignancies. 2021. 13(11): p. 2607.
Roy, S.R. and F.J.J.o.N.I.o.O. Huque, An Overview of Childhood Ocular, Orbital and Surface Tumor with Clinical Updates. 2022. 5(1): p. 51-68.
Sharma, A., et al., Navigating the Landscape of Cancer-Induced Thrombocytopenia: Current Challenges and Emerging Advances. 2024: p. 435-463.
Yang, Z., et al., B lymphocytes transdifferentiate into immunosuppressive erythroblast-like cells. 2023. 14: p. 1202943.
Suterwala, B.J.P.-o.-C.Q.R., Solid Tumors in Childhood. 2024.
Cheung, S.A., et al., Pediatric oncology drug development and dosage optimization. 2024. 13: p. 1235947.
Gllareva, E., Prognostic significance of preoperative anemia on occurrence of regional metastases and other primary tumors in patients with early stage oral squamous cell carcinoma. 2023, University of Zagreb. School of Medicine.
Xiaofeng, N., et al., Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer. 2023. 23(1): p. 349.
Shrivastava, N. and A.F. O’Neill, Update in Solid Tumors of Childhood, in Update in Pediatrics. 2024, Springer. p. 629-662.
Malinowska, I., et al., Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation-single center experience. 2021. 60(3): p. 103077.
Zhu, H.-D., et al., TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial. 2022. 32(11): p. 7335-7343...
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
